Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
A Phase I/II, Open-Label, Single-arm, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.
Sponsor: Shouyao Holdings (Beijing) Co. LTD
Listed as NCT05278364, this PHASE1/PHASE2 trial focuses on Medullary Thyroid Cancer and Non-Small Cell Lung Cancer and remains ongoing. Sponsored by Shouyao Holdings (Beijing) Co. LTD, it has been updated 7 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
May 2025 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Apr 2022 — Mar 2023 [monthly]
Recruiting PHASE1
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shouyao Holdings (Beijing) Co. LTD
For direct contact, visit the study record on ClinicalTrials.gov .